17 October 2024
17 October 2024
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.
Eli Lilly鈥檚 senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
The company secured claims to its iPSC-programming technology, deemed novel and inventive by the EPO.
Viatris will make an upfront payment of $25m to Lexicon.
The authorisation by Health Canada is based on the positive outcomes from the Phase III LAVENDER trial.
Onychomycosis is a serious fungal infection impacting an estimated 5.5% of the world's population.
The partnership unites RAD's products with AtomVie's capabilities in the manufacture and distribution of radiopharmaceuticals.
The deal aims to fill a crucial gap in medical countermeasures for radiation exposure.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
